A Study To Evaluate Gene Therapy For Propionic Acidemia Patients

Overview

About this study

The purpose of this study is to evaluate the safety and potential benefit of immunomodulatory gene therapy designed to minimize the immune response.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Age six months to 2 years of age at day of vector infusion.

  • Diagnosis of propionic acidemia with biallelic PCCA gene mutations.

  • Parents of study participants must agree to comply in good faith with the conditions of the study, including attending all of the required baseline and follow-up.assessments, and parents or legal guardians must give consent for their child's participation.

Exclusion Criteria:

  • Active viral infection (includes HIV or serology positive for hepatitis B or C).

  • ELISA positive for neutralizing anti-AAV10 capsid IgG antibodies (> 1:5).

  • Previous liver transplant.

  • Family does not want to disclose patient's study participation with primary care physician and other medical providers.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

David Deyle, M.D.

Contact us for the latest status

Contact information:

Clinical Genomics Research

(507) 538-6151

RSTCGRESEARCH@mayo.edu

More information

Publications

Publications are currently not available